Cardiomyocyte dimethylarginine dimethylaminohydrolase-1 (DDAH1) plays an important role in attenuating ventricular hypertrophy and dysfunction

Xin Xu, Ping Zhang, Dongmin Kwak, John Fassett, Wenhui Yue, Dorothee Atzler, Xinli Hu, Xiaohong Liu, Huan Wang, Zhongbing Lu, Haipeng Guo, Edzard Schwedhelm, Rainer H. Böger, Peijie Chen, Yingjie Chen

Research output: Contribution to journalArticle

13 Scopus citations

Abstract

Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of nitric oxide synthases that limits nitric oxide bioavailability. Dimethylarginine dimethylaminohydrolase-1 (DDAH1) exerts a critical role for ADMA degradation and plays an important role in NO signaling. In the heart, DDAH1 is observed in endothelial cells and in the sarcolemma of cardiomyocytes. While NO signaling is important for cardiac adaptation to stress, DDAH1 impact on cardiomyocyte homeostasis is not clear. Here we used the MerCreMer-LoxP model to specifically disrupt cardiomyocyte DDAH1 expression in adult mice to determine the physiological impact of cardiomyocyte DDAH1 under basal conditions and during hypertrophic stress imposed by transverse aortic constriction (TAC). Under control conditions, cardiomyocyte-specific DDAH1 knockout (cDDAH KO) had no detectable effect on plasma ADMA and left ventricular (LV) hypertrophy or function in adult or aging mice. In response to TAC, DDAH1 levels were elevated 2.5-fold in WT mice, which exhibited no change in LV or plasma ADMA content and moderate LV hypertrophy and LV dysfunction. In contrast, cDDAH1 KO mice exposed to TAC showed no increase in LV DDAH1 expression, slightly increased LV tissue ADMA levels, no increase in plasma ADMA, but significantly exacerbated LV hypertrophy, fibrosis, nitrotyrosine production, and LV dysfunction. These findings indicate cardiomyocyte DDAH1 activity is dispensable for cardiac function under basal conditions, but plays an important role in attenuating cardiac hypertrophy and ventricular remodeling under stress conditions, possibly through locally confined regulation of subcellular ADMA and NO signaling.

Original languageEnglish (US)
Article number55
JournalBasic Research in Cardiology
Volume112
Issue number5
DOIs
StatePublished - Sep 1 2017

Keywords

  • ADMA
  • Nitric oxide
  • Ventricular hypertrophy

Fingerprint Dive into the research topics of 'Cardiomyocyte dimethylarginine dimethylaminohydrolase-1 (DDAH1) plays an important role in attenuating ventricular hypertrophy and dysfunction'. Together they form a unique fingerprint.

  • Cite this

    Xu, X., Zhang, P., Kwak, D., Fassett, J., Yue, W., Atzler, D., Hu, X., Liu, X., Wang, H., Lu, Z., Guo, H., Schwedhelm, E., Böger, R. H., Chen, P., & Chen, Y. (2017). Cardiomyocyte dimethylarginine dimethylaminohydrolase-1 (DDAH1) plays an important role in attenuating ventricular hypertrophy and dysfunction. Basic Research in Cardiology, 112(5), [55]. https://doi.org/10.1007/s00395-017-0644-z